arrow
M

Mathew G. Angelos

Department of Medicine
H指数:14
被引数:881

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Phase 1/1b Study of the All-Oral Regimen CC-486 and Venetoclax in Acute Myeloid Leukemia

一项CC-486和Venetoclax口服方案在急性髓系白血病中的I/1b期研究

2026-07-280
OA
Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia

新诊断急性髓系白血病患者的耐受性与结局:接受连续28天周期性Venetoclax治疗的研究

2026-02-130
PRE
CD5 deletion enhances the antitumor activity of adoptive T cell therapies

CD5缺失增强过继性T细胞疗法的抗肿瘤活性

2024-07-195
PRE
Translational insights from a phase 1, first-in-human (FIH) clinical trial of the anti-HER2 CAR macrophage CT-0508 in participants with HER2 positive metastatic breast cancer and other HER2 overexpressing solid tumors
2024-05-021
PRE
Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study

靶向CD19近膜域的新型anti-CD19嵌合抗原受体T细胞产品对非霍奇金淋巴瘤的安全性和有效性: 一项首次人体研究

2023-12-098
OAAI
A phase 1, first-in-human (FIH) study of autologous anti-HER2 chimeric antigen receptor macrophage (CAR-M) in participants (pt) with HER2 overexpressing solid tumors
2023-04-140
PRE